MANGALAM DRUGS & ORGANICS LTD.

Mangalam Drugs & Organics Ltd has filed an intimation regarding a subsequent default on its bank loan obligations. The company has defaulted on loan accounts with Bank of Maharashtra and Bank of Baroda for a period exceeding 30 days. The overdue amount for Bank of Maharashtra is ₹951.19 Lacs, with the default starting on October 17, 2025. For Bank of Baroda, the overdue amount is ₹606.08 Lacs, with the default commencing on October 20, 2025. The company states it is making arrangements to pay the overdue amounts as soon as possible.

Mangalam Drugs & Organics Ltd has filed an intimation regarding a subsequent default on its bank loan obligations. The company has defaulted on payments to Bank of Baroda and Bank of Maharashtra for a period exceeding 30 days. The overdue amounts are ₹606.08 Lacs for Bank of Baroda and ₹951.19 Lacs for Bank of Maharashtra, with the defaults starting on October 20, 2025, and October 17, 2025, respectively. The company states it is making arrangements to pay the overdue amounts as soon as possible.

Mangalam Drugs & Organics Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code. The trading window will be shut from July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the period ending June 30, 2026. This measure is standard practice to prevent potential insider trading before the official announcement of financial performance.

Mangalam Drugs & Organics Ltd has disclosed a default on its bank loan obligations to Bank of Baroda and Bank of Maharashtra, with the overdue amount exceeding 30 days. The total overdue amount is approximately ₹1558.05 lacs. The company is reportedly making arrangements to clear the overdue amounts as soon as possible. This disclosure is made in compliance with SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Mangalam Drugs and Organics Limited has reported subsequent defaults on its loan obligations to Bank of Baroda and Bank of Maharashtra for a period exceeding 30 days. As of May 15, 2026, the amount overdue to Bank of Maharashtra is ₹951.97 Lacs since October 17, 2025, and to Bank of Baroda is ₹606.08 Lacs since October 20, 2025. The company is arranging to pay the overdue amount as soon as possible.

Mangalam Drugs & Organics Ltd approved standalone and consolidated financial results for the quarter and year ended March 31, 2026, during its board meeting held on May 14, 2026. The statutory auditors have not expressed any modified opinions in their audit reports. The board meeting commenced at 12:30 P.M. and concluded at 3:45 P.M.

Mangalam Drugs & Organics Ltd declared audited standalone and consolidated financial results for the year ended March 31, 2026, following a board meeting held on May 14, 2026. The statutory auditors have issued an unmodified opinion on the audited financial results. The board meeting commenced at 12:30 P.M. and concluded at 3:45 P.M.

Mangalam Drugs & Organics Ltd has announced a Board of Directors meeting scheduled for May 14, 2026, to consider and approve the audited financial results (standalone & consolidated) for the quarter and year ended March 31, 2026. The trading window for dealing in the company's securities has been closed for Directors/Officers and designated employees from April 1, 2026, and will remain closed until 48 hours after the announcement of the audited financial results.

Mangalam Drugs & Organics Ltd. announced that its promoter, Shree Rasbihari Trading and Investments Private Limited, has released 1,73,000 pledged equity shares. This release, reported under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, represents 1.09% of the company's total share capital. The shares were released from pledge on March 16, 2026. This action reduces the encumbered holding of the promoter group, potentially signaling improved financial stability or reduced leverage requirements for the promoter.

Mangalam Drugs & Organics Ltd announced that its promoter, Shree Kishoriju Trading and Investments Private Limited, has released previously pledged shares. The disclosure, submitted on April 29, 2026, under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, confirms that the encumbrance on shares held by the promoter group was released on February 6, 2026. Following this release, the promoter group's post-event holding of encumbered shares is now 0.00%. This action signifies an improvement in the promoter's unencumbered shareholding position.